Zontivity

This page shows the latest Zontivity news and features for those working in and with pharma, biotech and healthcare.

FDA reviewer backs approval of TMC's cangrelor

Additional competition in the category will also come from Merck &Co's first-in-class protease-activated receptor-1 (PAR-1) antagonist Zontivity (vorapaxar) - which was cleared for marketing in the

Latest news

R&D productivity takes off

Other first-in-class agents include: Merck &Co's PAR-1 antagonist Zontivity (vorapaxar), a novel antiplatelet agent; AstraZeneca's PARP inhibitor Lynparza (olaparib) for cancer; Otsuka's Deltyba (delamanid), a
Orphan drugs in latest CHMP recommendations

s Zontivity (vorapaxar), which was recommended for the reduction of atherothrombotic events.
Merck's first-in-class Zontivity cleared in US

Merck's first-in-class Zontivity cleared in US. FDA approves the protease-activated receptor-1 antagonist to reduce heart attack risk. ... Merck plans to launch Zontivity in the US in the coming weeks, while the PAR-1 antagonist is also under regulatory
FDA panel backs Merck's vorapaxar

Vorapaxar - which Merck plans to sell under the brand name Zontivity - is an orally-active protease-activated receptor 1 (PAR-1) inhibitor that targets thrombin-induced platelet activation. ... If the FDA follows the panel's advice - which it generally

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Deal Watch September 2016

Merck &Co has sold the US and Canadian rights for its Zontivity, or vorapaxar, to Aralez Pharmaceuticals in an asset purchase agreement worth $25m. ... Zontivity is a protease-activated receptor-1 antagonist indicated for use in combination with daily

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Associate Editorial Director – Med Comms – London: Salary TBC

Associate Director: £75, 000-90, 000

Consumer Health Account Director: Circa £60, 000 Gym and More

Account Director: £48, 000 - £60, 000

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Account Director: Excellent benefits

Senior Medical Writer (Remote Working): Competitive Salary Offered

Events Manager – Med Comms – Surrey: Salary TBC

New Business Director - PR: Competitive Salary and benefits

Senior Account Manager: Negotiable

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Systematic Review Analyst - Oxford: Negotiable

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Senior Account Director development role to Business Director, H...: Excellent package

Medical Writers Required – Cheshire: DOE

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Senior Medical Writer: Competitive Salary

Consultant Health Economics - London / Oxford: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health: For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...